Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endolipide is an intravenous lipid emulsion, typically containing 20% soybean oil, used primarily as a source of energy and essential fatty acids in parenteral nutrition. In the context of clinical research, specifically a Phase 3 academic study conducted by Assistance Publique - Hôpitaux de Marseille (NCT01083472), Endolipide is utilized as a standardized lipid challenge to investigate metabolic regulation. The study evaluates the acute effects of intensive insulin therapy on the production and metabolism of intestinal triglyceride-rich lipoproteins (TRLs) in adults with type 2 diabetes mellitus. By administering Endolipide, researchers can maintain stable plasma lipid levels (a "lipid clamp") to observe how insulin modulates the assembly and secretion of chylomicrons and other lipoproteins, providing insights into the pathophysiology of diabetic dyslipidemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on soybean oil (Assistance Publique-Hôpitaux de Marseille).